Related Experiment Video
Updated: Jan 16, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
Published on: June 14, 2016
Sirtuin-mediated modulation of cardiac fibrosis: Emerging molecular insights and therapeutic perspectives
Claudia Cozzolino1, Erica Floris1, Francesca Icolaro1
1Department of Medical Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, Latina 04100, Italy.
Abstract:
Fibrosis is a fundamental pathological process driving heart failure progression by promoting extracellular matrix deposition and impairing myocardial compliance. In recent years, the sirtuin family of NAD⁺-dependent deacetylases, traditionally linked to aging and metabolism, has emerged as a key regulator of cardiac fibrotic remodeling. This review investigates the roles of sirtuins in mitigating cardiac fibrosis, with emphasis on mechanisms such as mitochondrial preservation and the therapeutic potential of their modulation. Sirtuin signaling attenuates fibrosis by regulating intracellular pathways that control fibroblast activation. In particular, sirtuin-mediated deacetylation modulates pro-fibrotic mediators, including the TGF-β/Smad pathway, thereby reducing collagen synthesis and fibrotic gene expression. However, their effects are isoform- and context-dependent: SIRT1, SIRT3, SIRT6, and SIRT7 generally exert protective roles, whereas SIRT2 and SIRT5 may display neutral or even pro-fibrotic actions depending on the cell type, disease stage, and experimental context. Recognizing this complexity is essential to evaluate their therapeutic relevance. Building on these mechanistic insights, the review explores the preclinical development of sirtuin-targeted therapies. Strategies include NAD⁺ precursors, natural compounds, novel small-molecule activators with enhanced specificity, and agents that indirectly stimulate sirtuins through metabolic modulation. Such approaches highlight the potential of pharmacologically enhancing sirtuin activity to counteract maladaptive cardiac remodeling and improve outcomes in heart failure. By integrating molecular insights with advances in pharmacology, this review synthesizes the most recent mechanistic findings from the past three years with a dedicated focus on the translational challenges and opportunities of pharmacologically targeting sirtuins for anti-fibrotic therapy.
Insights
Sirtuins regulate cardiac fibrosis, with specific isoforms like SIRT1 and SIRT3 offering protective roles against heart failure. Targeting sirtuins presents a promising therapeutic strategy for mitigating fibrotic remodeling.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pharmacology
Background:
- Fibrosis is a key driver of heart failure progression, characterized by excessive extracellular matrix deposition.
- The sirtuin family of NAD⁺-dependent deacetylases, known for roles in aging and metabolism, are emerging as critical regulators of cardiac fibrotic remodeling.
Purpose of the Study:
- To review the multifaceted roles of sirtuins in mitigating cardiac fibrosis.
- To explore the mechanisms by which sirtuins influence fibroblast activation and extracellular matrix production.
- To assess the therapeutic potential of modulating sirtuin activity for treating heart failure.
Main Methods:
- Literature review focusing on mechanistic insights and preclinical studies from the past three years.
- Analysis of sirtuin isoform-specific effects on pro-fibrotic pathways, including the TGF-β/Smad pathway.
- Examination of various therapeutic strategies targeting sirtuin activation.
Main Results:
- Sirtuin signaling generally attenuates cardiac fibrosis by regulating fibroblast activation and collagen synthesis.
- Specific isoforms (SIRT1, SIRT3, SIRT6, SIRT7) typically exert protective effects, while others (SIRT2, SIRT5) can be context-dependent.
- Preclinical therapeutic strategies include NAD⁺ precursors, natural compounds, and specific small-molecule activators.
Conclusions:
- Sirtuin modulation holds significant therapeutic potential for counteracting maladaptive cardiac remodeling in heart failure.
- Understanding the isoform- and context-dependent actions of sirtuins is crucial for effective therapeutic development.
- Pharmacological enhancement of sirtuin activity offers a promising avenue for anti-fibrotic therapy in cardiovascular disease.
